Suzanne Dahlberg

Publications

1. Health-related quality of life in children with bronchopulmonary dysplasia: examining agreement between child self-report and parent proxy. Eur J Pediatr. 2024 Nov 21; 184(1):36. View Abstract
2. Ambient smoke exposure and indoor air quality in eastern Massachusetts during the 2023 wildfire season. J Air Waste Manag Assoc. 2024 Nov; 74(11):820-827. View Abstract
3. Comparison of home-based spirometry and oscillometry measurements in school-age children with bronchopulmonary dysplasia. Pediatr Pulmonol. 2024 Oct; 59(10):2589-2596. View Abstract
4. Virtual interviews and equity: The pediatric pulmonary fellow perspective. Pediatr Pulmonol. 2024 Jun; 59(6):1731-1739. View Abstract
5. Gastrointestinal complications in pediatric lung transplant recipients: Incidence, risk factors, and effects on patient outcomes. Pediatr Transplant. 2024 Feb; 28(1):e14665. View Abstract
6. Pericytes contribute to pulmonary vascular remodeling via HIF2a signaling. EMBO Rep. 2024 Feb; 25(2):616-645. View Abstract
7. Germline EGFR Mutations and Familial Lung Cancer. J Clin Oncol. 2023 Dec 01; 41(34):5274-5284. View Abstract
8. Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) RNA and viable virus contamination of hospital emergency department surfaces and association with patient coronavirus disease 2019 (COVID-19) status and aerosol-generating procedures. Infect Control Hosp Epidemiol. 2024 Feb; 45(2):244-246. View Abstract
9. Comparison of Pneumotachometer and Portable Digital Turbine Spirometry for Field-Based Assessment: An Air Quality, Environment, and Respiratory Outcomes in Bronchopulmonary Dysplasia Study. Pediatr Allergy Immunol Pulmonol. 2023 09; 36(3):115-118. View Abstract
10. Parental awareness and management of bullying in children with food allergies. J Allergy Clin Immunol Pract. 2023 Oct; 11(10):3257-3259.e2. View Abstract
11. Health-Related Qualities of Life in School-Aged Children with Bronchopulmonary Dysplasia. J Pediatr. 2023 10; 261:113548. View Abstract
12. Trends in Pregnancy Rates in an Urban Adolescent Clinic Before and During the COVID-19 Pandemic. Clin Pediatr (Phila). 2023 06; 62(5):481-484. View Abstract
13. Real-world feasibility of short-term, unsupervised home spirometry in CF. Pediatr Pulmonol. 2022 12; 57(12):3129-3135. View Abstract
14. Binge-eating behaviors in adolescents and young adults during the COVID-19 pandemic. J Eat Disord. 2022 Aug 24; 10(1):125. View Abstract
15. Eating disorders in adolescents and young adults with cystic fibrosis. Pediatr Pulmonol. 2022 11; 57(11):2791-2797. View Abstract
16. Bone density and bone marrow composition in transgender girls prior to pubertal blockade: A case series. Bone. 2022 09; 162:116454. View Abstract
17. Lung-MAP: A Collaborative Roadmap to Improve Cancer Outcomes. J Clin Oncol. 2022 07 20; 40(21):2285-2287. View Abstract
18. Use of an Educational Video to Improve Transgender Health Care Knowledge. Clin Pediatr (Phila). 2022 06; 61(5-6):412-417. View Abstract
19. Efficacy and Safety of High-dose Cholecalciferol in Patients With Inflammatory Bowel Disease Receiving Infliximab. J Pediatr Gastroenterol Nutr. 2022 04 01; 74(4):476-483. View Abstract
20. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021 11; 27(11):1910-1920. View Abstract
21. Peer-to-Peer Social Media Communication About Dietary Supplements Used for Weight Loss and Sports Performance Among Military Personnel: Pilot Content Analysis of 11 Years of Posts on Reddit. JMIR Form Res. 2021 Oct 04; 5(10):e28957. View Abstract
22. Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504). JTO Clin Res Rep. 2021 May; 2(5):100166. View Abstract
23. Attitudes towards involving children in decision-making surrounding lung transplantation. Pediatr Pulmonol. 2021 06; 56(6):1534-1542. View Abstract
24. Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial. J Thorac Oncol. 2021 06; 16(6):960-967. View Abstract
25. Is Ovarian Reserve Impacted in Anorexia Nervosa? J Pediatr Adolesc Gynecol. 2021 Apr; 34(2):196-202. View Abstract
26. Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial. Cancer Med. 2020 10; 9(20):7511-7523. View Abstract
27. Clinical Versus Statistical Significance in Studies of Thoracic Malignancies. J Thorac Oncol. 2020 09; 15(9):1406-1408. View Abstract
28. Identification of a RAS-activating TMEM87A-RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 08 01; 26(15):4072-4079. View Abstract
29. Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib. J Thorac Imaging. 2020 Mar; 35(2):101-107. View Abstract
30. Use of ExVivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 05 15; 26(10):2393-2403. View Abstract
31. Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib. Eur J Radiol Open. 2020; 7:100210. View Abstract
32. Reply to N. Hanna et al and L. Xie et al. J Clin Oncol. 2020 03 01; 38(7):771-772. View Abstract
33. Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019; 3. View Abstract
34. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol. 2019 10 01; 30(10):1653-1659. View Abstract
35. Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019 10; 14(10):1718-1731. View Abstract
36. Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508. J Clin Oncol. 2019 09 10; 37(26):2360-2367. View Abstract
37. Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. J Clin Oncol. 2019 08 01; 37(22):1927-1934. View Abstract
38. Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer Discov. 2019 07; 9(7):926-943. View Abstract
39. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer. 2019 07; 133:96-102. View Abstract
40. Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome. Eur J Radiol Open. 2019; 6:128-131. View Abstract
41. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. J Immunother Cancer. 2019 03 28; 7(1):87. View Abstract
42. M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome. Oncologist. 2019 08; 24(8):e749-e754. View Abstract
43. Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. J Clin Oncol. 2019 01 20; 37(3):222-229. View Abstract
44. Clinical Trials, End Points, and Statistics-Measuring and Comparing Cancer Treatments in Practice. JAMA Oncol. 2018 12 01; 4(12):1798. View Abstract
45. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol. 2018 11 01; 4(11):1527-1534. View Abstract
46. Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm. Eur J Radiol. 2018 Dec; 109:68-76. View Abstract
47. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2018 11; 13(11):1655-1667. View Abstract
48. Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations. J Thorac Oncol. 2018 11; 13(11):1625-1637. View Abstract
49. Pragmatic approaches to address expansion cohort design. Cancer. 2018 08; 124(16):3290-3292. View Abstract
50. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. J Clin Oncol. 2018 07 01; 36(19):1905-1912. View Abstract
51. Interpretation of Results from Under-accruing Studies. Oncologist. 2018 07; 23(7):755-756. View Abstract
52. Evaluation of End Points in Cancer Clinical Trials. J Thorac Oncol. 2018 06; 13(6):745-747. View Abstract
53. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas. Cancer Cytopathol. 2018 04; 126(4):253-263. View Abstract
54. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2017 12; 18(12):1610-1623. View Abstract
55. Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. Clin Cancer Res. 2017 Oct 01; 23(19):5737-5744. View Abstract
56. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol. 2016 Dec; 17(12):1661-1671. View Abstract
57. Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development. Cancer. 2016 Nov 15; 122(22):3456-3463. View Abstract
58. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol. 2016 Aug 01; 2(8):1014-22. View Abstract
59. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. Clin Cancer Res. 2016 Dec 15; 22(24):6010-6020. View Abstract
60. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer. 2016 Aug 01; 122(15):2371-8. View Abstract
61. Multicenter Evaluation of Clinical Diagnostic Methods for Detection and Isolation of Campylobacter spp. from Stool. J Clin Microbiol. 2016 05; 54(5):1209-15. View Abstract
62. Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. JAMA Oncol. 2016 Mar; 2(3):313-20. View Abstract
63. Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer. Clin Cancer Res. 2016 07 01; 22(13):3148-56. View Abstract
64. Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. Acad Radiol. 2016 Mar; 23(3):329-36. View Abstract
65. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol. 2016 Mar 01; 34(7):721-30. View Abstract
66. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr; 11(4):556-65. View Abstract
67. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. Clin Cancer Res. 2015 Dec 15; 21(24):5439-44. View Abstract
68. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. J Thorac Oncol. 2015 Dec; 10(12):1726-35. View Abstract
69. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul; 10(7):1099-106. View Abstract
70. A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511). Lung Cancer. 2015 Jul; 89(1):66-70. View Abstract
71. Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. Cancer. 2015 Aug 01; 121(15):2570-7. View Abstract
72. Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). Cancer. 2015 Jul 01; 121(13):2253-61. View Abstract
73. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. Clin Cancer Res. 2015 Jun 15; 21(12):2851-60. View Abstract
74. Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival. Eur J Radiol. 2015 May; 84(5):998-1004. View Abstract
75. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015 Apr; 88(1):108-11. View Abstract
76. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63. View Abstract
77. Improving Clinical Trial Efficiency: Thinking outside the Box. Am Soc Clin Oncol Educ Book. 2015; e141-7. View Abstract
78. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015 Mar; 29(3):526-34. View Abstract
79. Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience. J Natl Cancer Inst. 2014 Jul; 106(7). View Abstract
80. Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501). Cancer Chemother Pharmacol. 2014 Jul; 74(1):177-83. View Abstract
81. E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol. 2014 Jan; 73(1):171-80. View Abstract
82. Presentation, treatment, and outcome differences between men and women undergoing revascularization or amputation for lower extremity peripheral arterial disease. J Vasc Surg. 2014 Feb; 59(2):409-418.e3. View Abstract
83. Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials. J Thorac Oncol. 2013 Sep; 8(9):1121-7. View Abstract
84. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013 Nov 01; 119(21):3776-83. View Abstract
85. Baseline tumour measurements predict survival in advanced non-small cell lung cancer. Br J Cancer. 2013 Sep 17; 109(6):1476-81. View Abstract
86. Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. Cancer. 2013 Nov 01; 119(21):3761-8. View Abstract
87. Fate of the contralateral limb after lower extremity amputation. J Vasc Surg. 2013 Dec; 58(6):1571-1577.e1. View Abstract
88. Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. J Thorac Oncol. 2013 Aug; 8(8):1059-68. View Abstract
89. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep; 49(14):2972-8. View Abstract
90. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet Oncol. 2013 Jun; 14(7):619-26. View Abstract
91. Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594. Lung Cancer. 2013 Jul; 81(1):47-52. View Abstract
92. Outcomes following infrapopliteal angioplasty for critical limb ischemia. J Vasc Surg. 2013 Jun; 57(6):1455-63; discussion 1463-4. View Abstract
93. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb; 8(2):179-84. View Abstract
94. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013 Mar 20; 31(9):1202-10. View Abstract
95. Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer. 2013 Mar; 79(3):283-8. View Abstract
96. Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes. Pediatrics. 2012 Dec; 130(6):1003-11. View Abstract
97. Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol. 2012 Sep; 7(9):1361-8. View Abstract
98. Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. Dis Model Mech. 2012 Nov; 5(6):881-94. View Abstract
99. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol. 2012 Aug 01; 30(22):2788-97. View Abstract
100. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med. 2012 Jul; 18(7):1118-22. View Abstract
101. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012 Apr 01; 30(10):1042-9. View Abstract
102. Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. J Clin Oncol. 2012 Feb 20; 30(6):616-22. View Abstract
103. Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. Lung Cancer. 2012 Jun; 76(3):410-5. View Abstract
104. SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. Oncogene. 2012 Sep 13; 31(37):4107-16. View Abstract
105. Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov. 2012 Jan; 2(1):47-55. View Abstract
106. The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. Blood. 2011 Oct 13; 118(15):4169-73. View Abstract
107. Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. J Exp Med. 2011 Aug 01; 208(8):1595-603. View Abstract
108. Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. Pediatr Blood Cancer. 2011 Sep; 57(3):492-8. View Abstract
109. The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. Oncol Rep. 2011 Jun; 25(6):1765-72. View Abstract
110. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011 Feb; 152(4):452-9. View Abstract
111. Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. J Thorac Oncol. 2011 Jan; 6(1):103-8. View Abstract
112. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol. 2010 Sep; 5(9):1416-23. View Abstract
113. Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):3816-23. View Abstract
114. Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study. J Thorac Oncol. 2010 Jun; 5(6):885-92. View Abstract
115. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood. 2010 Apr 08; 115(14):2845-51. View Abstract
116. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol. 2010 Feb 20; 28(6):949-54. View Abstract
117. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol. 2009 Dec 10; 27(35):6006-11. View Abstract
118. Population-based outcomes following endovascular and open repair of ruptured abdominal aortic aneurysms. J Endovasc Ther. 2009 Oct; 16(5):554-64. View Abstract
119. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2009 Aug; 53(2):162-7. View Abstract
120. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009 Jul 16; 114(3):647-50. View Abstract
121. Predictors of failure after angioplasty of infrainguinal vein bypass grafts. J Vasc Surg. 2009 Jan; 49(1):117-21. View Abstract
122. Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal. J Clin Oncol. 2008 Sep 10; 26(26):4233-5. View Abstract
123. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol. 2008 Mar 01; 26(7):1106-11. View Abstract
124. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008 Jan 01; 26(1):60-5. View Abstract
125. A proportional hazards cure model for the analysis of time to event with frequently unidentifiable causes. Biometrics. 2007 Dec; 63(4):1237-44. View Abstract
126. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol. 2007 Nov; 2(11):1036-41. View Abstract
127. RrgA is a pilus-associated adhesin in Streptococcus pneumoniae. Mol Microbiol. 2007 Oct; 66(2):329-40. View Abstract
128. Lower extremity arterial revascularization in obese patients. J Vasc Surg. 2007 Oct; 46(4):738-42. View Abstract
129. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood. 2007 Sep 01; 110(5):1607-11. View Abstract
130. Modelling menstrual status during and after adjuvant treatment for breast cancer. Stat Med. 2006 Oct 30; 25(20):3534-47. View Abstract
131. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001 Sep 15; 19(18):3852-60. View Abstract
132. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group. Bone Marrow Transplant. 2000 Feb; 25(3):283-91. View Abstract
133. Phase II trial of menogaril in non-Hodgkin's lymphomas: a Southwest Oncology Group trial. Invest New Drugs. 1999; 17(2):169-72. View Abstract
134. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998 Jul 02; 339(1):21-6. View Abstract
135. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. J Clin Oncol. 1998 Jan; 16(1):48-55. View Abstract
136. Left ventricular cavity size determined by preoperative dipyridamole thallium scintigraphy as a predictor of late cardiac events in vascular surgery patients. Am Heart J. 1996 May; 131(5):907-14. View Abstract
137. Design and analysis of multiarm clinical trials with survival endpoints. Control Clin Trials. 1995 Apr; 16(2):119-30. View Abstract
138. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood. 1995 Feb 15; 85(4):1075-82. View Abstract
139. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med. 1994 Jun 01; 120(11):903-12. View Abstract
140. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood. 1994 Mar 15; 83(6):1460-6. View Abstract
141. Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: a Southwest Oncology Group study. Hematol Oncol. 1994 Mar-Apr; 12(2):75-85. View Abstract
142. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol. 1994; 5 Suppl 2:91-5. View Abstract
143. Selection designs for pilot studies based on survival. Biometrics. 1993 Jun; 49(2):391-8. View Abstract
144. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993 Apr 08; 328(14):1002-6. View Abstract
145. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol. 1993 Apr; 11(4):644-51. View Abstract
146. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer. 1993 Jan 15; 71(2 Suppl):618-27. View Abstract
147. Treatment of diffuse large-cell lymphoma: a summary of outcome for patients treated by Southwest Oncology Group. Cancer Treat Res. 1993; 66:53-63. View Abstract
148. Predictors of surgical mortality and long-term results of endocardial resection for drug-refractory ventricular tachycardia. Am Heart J. 1992 Nov; 124(5):1226-32. View Abstract
149. Planned versus attained design in phase II clinical trials. Stat Med. 1992 May; 11(7):853-62. View Abstract
150. Prognostic factors in clinical trials. Breast Cancer Res Treat. 1992; 22(3):193-6. View Abstract
151. Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group study. J Clin Oncol. 1991 Jul; 9(7):1204-9. View Abstract
152. Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: a Southwest Oncology Group study. J Clin Oncol. 1991 May; 9(5):748-53. View Abstract
153. A clinical phase II study of ProMACE-CytaBOM. J Clin Oncol. 1991 May; 9(5):888. View Abstract
154. Alternated versus syncopated CHOP-PVB: two studies for the treatment of non-Hodgkin's lymphoma by the Southwest Oncology Group. Cancer Invest. 1991; 9(6):613-20. View Abstract
155. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study. J Clin Oncol. 1990 Dec; 8(12):1951-8. View Abstract
156. Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study. J Natl Cancer Inst. 1990 Aug 15; 82(16):1353-5. View Abstract
157. m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial. J Clin Oncol. 1990 Jul; 8(7):1155-62. View Abstract
158. Phase II evaluation of bisantrene in acute leukemia. A Southwest Oncology Group Study. Am J Clin Oncol. 1989 Dec; 12(6):507-10. View Abstract
159. Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: a Southwest Oncology Group phase II trial. Invest New Drugs. 1989 Jul; 7(2-3):247-50. View Abstract
160. Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission. J Clin Oncol. 1989 Mar; 7(3):326-37. View Abstract
161. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood. 1989 Jan; 73(1):57-63. View Abstract
162. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988 Aug; 72(2):546-54. View Abstract
163. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood. 1988 Aug; 72(2):555-61. View Abstract
164. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin Hematol. 1988 Apr; 25(2 Suppl 2):17-22. View Abstract
165. Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin Hematol. 1987 Apr; 24(2 Suppl 1):21-5. View Abstract
166. Hodgkin's disease in the United States: a comparison of patient characteristics and survival in the Centralized Cancer Patient Data System and the Surveillance, Epidemiology, and End Results Program. J Natl Cancer Inst. 1987 Mar; 78(3):471-8. View Abstract
167. HLA and leprosy in Koreans. Tissue Antigens. 1987 Mar; 29(3):146-53. View Abstract
168. The HLA system in the Korean population. Hum Immunol. 1986 Nov; 17(3):259-72. View Abstract
169. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood. 1986 Mar; 67(3):811-6. View Abstract
170. Race, socioeconomic status, and other prognostic factors for survival from prostate cancer. J Natl Cancer Inst. 1985 May; 74(5):1001-6. View Abstract
171. Incidence of hypertension after marrow transplantation among 112 patients randomized to either cyclosporine or methotrexate as graft-versus-host disease prophylaxis. Br J Haematol. 1985 Mar; 59(3):547-53. View Abstract
172. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intern Med. 1984 Nov; 101(5):581-8. View Abstract
173. Some statistical methodology for the analysis of HLA data. Biometrics. 1984 Jun; 40(2):547-60. View Abstract
174. Accuracy of basic cancer patient data: results from an extensive recoding survey. J Natl Cancer Inst. 1984 May; 72(5):1007-14. View Abstract
175. Immunosuppressive therapy of severe aplastic anemia. Prog Clin Biol Res. 1984; 148:259-70. View Abstract
176. Combined modality therapy of advanced non-Hodgkin's lymphoma: an analysis of remission duration and survival in 95 patients. Blood. 1983 Jul; 62(1):51-61. View Abstract
177. A profile of treatment approaches used at comprehensive cancer centers. J Chronic Dis. 1982; 35(11):853-9. View Abstract
Show All Publications Show Fewer Publications